- 26 Feb 2007 13:01
Just wondered if anyone else out there is holding this company. I bought in a while ago just on the principle it would rise on the take-up by tracker fund managers due to its admission into the main market, and it has.
- 23 Oct 2013 08:25
- 2 of 30
Ex-divi wed 20th Nov (11.1p)
- 03 Sep 2014 08:14
- 3 of 30
Genus, a leading global animal genetics company, posts adjusted pre-tax profits of £39.3m for the year to the end of June - 8% down on last year in actual currencies and flat on a constant currency basis.
Revenues rose to £372.2m from £345.3m and statutory pre-tax profits were up 14% at £38.2m. The dividend is up 10% at 17.7p per share.
Adjusted earnings per share of 46.5p, up 3% in constant currency (down 5% in actual currency) with benefit of lower tax rate.
Chief executive Karim Bitar said: "We achieved a good performance in PIC and ABS in 2014, whilst Asia and specifically China was impacted by poor market conditions and the planned investments in expanding our porcine capacity. The strategic progress we have made positions us well to take advantage of improving market conditions. Although we face some continuing headwinds, we expect to perform in line with expectations in 2015."
- 14 Nov 2014 08:18
- 4 of 30
14 Nov 2014 Genus PLC GNS N+1 Singer Buy 1,265.50 1,260.00 1,287.00 1,287.00 Retains
- 14 Nov 2014 08:43
- 5 of 30
14 Nov 2014 Genus PLC GNS Liberum Capital Buy 1,264.50 1,260.00 1,400.00 1,400.00 Reiterates
- 14 Nov 2014 08:55
- 6 of 30
Genus, a leading global animal genetics company, today publishes a trading update for the period from 1 July 2014 to 13 November 2014.
Genus performed in line with expectations in the period under review. Genus's volumes, revenues and adjusted profit before tax for the first four months all increased compared with last year's performance. The growth in actual currency terms was at a lower rate than in constant currency.
Market conditions for Genus's bovine and porcine customers have generally been favourable with very good harvests in the Northern Hemisphere leading to falling input costs. Pork prices have been recovering in China, but the exceptionally high prices in North America over the summer have now reduced. Dairy prices globally have generally declined since the start of the financial year, while beef prices have remained elevated.
Genus PIC's profits improved with a continued strong performance in the Americas which benefited from improving market conditions and from Génétiporc, which had not been acquired until the end of the prior year period. Results in Europe were similar to the prior year. In September, PIC completed the acquisition for £6m of Birchwood Genetics Inc., a boar stud partner providing male PIC genetics to mid- and small-sized customers in the USA.
Dairy and beef volumes in Genus ABS grew in Europe and Latin America, while North America's overall volumes were stable. In aggregate, ABS increased revenues but higher product costs and expense phasing resulted in profits being slightly lower in the period.
In Genus Asia, bovine volumes grew, driven by China and India, while porcine volumes reduced due to lower shipments in Russia which has closed its border to imports from the EU and North America. Overall profits in Asia improved, with better performances in both species in China and in the Philippines, partially offset by lower profits in Russia.
Research and development spending was higher for the first four months on core research projects. We continued to invest in Genus Sexed Semen ('GSS'), with the successful completion of further large-scale field trials. Our previously announced US litigation relating to the GSS technology against Inguran LLC (trading as Sexing Technologies) continues, with a trial date set for early 2016 in the Western District of Wisconsin.
Genus maintains a strong financial position. Net debt at the end of October 2014 was lower than October 2013 but has increased compared with June 2014. The increase in net debt since the start of the year reflects the acquisition of Birchwood, exchange rate movements and expected seasonal cash flow patterns.
Genus is trading in line with our expectations for the full year. The headwinds experienced last year are abating as expected. As we continue to execute our strategy, we anticipate achieving growth expectations for the financial year 2015.
- 27 Nov 2014 15:28
- 8 of 30
70% of Chickens have bacteria..XMAS TRADE!!.... Beef = GNS GENUS Pork = CWK CRANSWICK as alternatives for chrissy dinner and parties etc.
GNS as the better chart and Ive found out they do both Beef and Pork.
Long on GNS
- 01 Dec 2014 08:31
- 9 of 30
01 Dec 2014 Genus PLC GNS Liberum Capital Buy 1,291.00 1,291.00 1,400.00 1,400.00 Reiterates
SP target 1400p
- 22 Dec 2014 08:14
- 10 of 30
22 Dec 2014 Genus PLC GNS Liberum Capital Buy 0.00 1,285.00 1,400.00 1,400.00 Reiterates
SP TARGET 1400p
- 16 Feb 2015 08:02
- 11 of 30
Genus, a leading global animal genetics company, has signed an agreement for the acquisition of 51% of the share capital of In Vitro Brasil SA through ABS, its bovine genetics business.
IVB is a leading biotechnology company focused on the production of bovine embryos through in-vitro fertilisation and the provision of associated services.
IVB is based in Brazil and also operates in a number of countries including the US, Colombia and Uruguay. Genus will acquire a 51% interest in IVB for a total investment consideration of BRL20m (£4.6m) in cash, including an upfront capital commitment.
Genus expects to acquire the remaining 49% of IVB's share capital in the first half of 2018 by exercising a call option. The selling shareholders also have a matching put option.
Consideration for the remaining 49% is conditional on certain performance conditions and is capped at BRL49m (£11.2m). The completion of the transaction is subject to a number of closing conditions, which are expected to be fulfilled in the first quarter of 2015. In 2014, IVB had global revenues in excess of £4m.
- 01 Apr 2015 09:23
- 12 of 30
Genus has completed the acquisition of 51% of In Vitro Brasil, a leading biotechnology company focused on the production of bovine embryos through in-vitro fertilisation and the provision of associated services.
Genus said IVB represents an excellent strategic fit with the group's core activities and is expected to strengthen Genus's global leadership in the development and delivery of differentiated genetics in the beef and dairy sectors through the introduction of IVF technology.
- 12 May 2015 09:56
- 13 of 30
Genus, a leading global animal genetics company, says it hasperformed in line with forecasts since the start of the year.
Genus's volumes, revenues and adjusted profit before tax all increased compared with last year's performance.
Genus says it continued to make good progress during the period under review towards our strategic objectives, and is trading in line with expectations for the financial year 2015.
Genus is holding a capital markets event today at 2 p.m. at which no material new information will be disclosed and Genus will not be commenting on current trading beyond what is announced in this statement.
The capital markets event will cover Genus's business model and the initiatives being implemented to further strengthen its position as a leader in the animal genetics market. The presentations given by Genus management will be made available on the company website tomorrow.
- 15 Sep 2015 11:18
- 14 of 30
Global animal genetics company Genus posts adjusted pre-tax profits of £46.6m for the year to the end of June - up from £39.3m last time and 23% higher at constant currencies.
The increase was driven mainly by a strong performance from the porcine division.
Revenues rose to £398.5m - up 7% and 8% higher at constant currencies. Adjusted operating profits increased to £47.2m - up from £42.9m. Adjusted operating profit including JVs rose to £51.2m from £44.8m.
Chief executive Karim Bitar said: "Genus performed well in 2015 achieving operational results that reflect the strategic progress and improvement we have been making. The opportunity in the animal genetics market remains large. We are convinced that as we vigorously execute our strategy of innovation and market focus, we will capture more of the market opportunity.
"While market conditions across our industries and geographies look likely to be mixed in 2016, we expect underlying performance to be in line with expectations. However, currencies remain a significant headwind."
- 08 Dec 2015 08:43
- 15 of 30
Genus tackles major pig disease with breakthrough technology
Genus (LSE: GNS), a global pioneer in animal genetics, announces the development of the first pigs resistant to Porcine Reproductive and Respiratory Syndrome Virus ("PRRSv"), through a long-standing collaboration with the University of Missouri.
The production of PRRSv resistant pigs is a significant breakthrough in combating this devastating porcine disease, and Genus is excited to be progressing the development of this technology under an exclusive global license from the University of Missouri.
PRRSv is the most significant and harmful pig disease faced by many farmers, causing animal reproductive failure, reduced growth and premature death. Even though it has challenged the pork industry for more than 25 years, there is currently no cure for PRRSv. The technology has the potential to eliminate the disease impact on the animals, improve the well-being of pigs, and enhance pig farm productivity, which ultimately will help meet the global demand for pork products.
Using precise gene editing, the University of Missouri was able to breed pigs that do not produce a specific protein necessary for the virus to spread in the animals. The early stage studies conducted by the University demonstrate these PRRSv resistant pigs, when exposed to the virus, do not get sick and continue to gain weight normally. Genus will continue to develop this technology, and we expect it will be at least five years until PRRS resistant animals are available to farmers. Genus intends to commercialize the technology through PIC, its porcine division.
- 23 Feb 2016 07:48
- 16 of 30
Genus, a leading animal genetics company, reports solid first half results and says its full year is on track.
Adjusted operating profits of GBP23.9m were 3% up at constant currencies but 2% at actual exchange rates. Adjusted operating profit, including joint ventures, totalled GBP26.3m - up 4% in constant currency but 3% lower in actual currency.
Revenues totalled GBP188.3m compared with GBP198.5m last time.
Chief executive Karim Bitar said: "Genus achieved a great deal during the first half of the year. Our performance was in line with our expectations and demonstrated the success of our strategy and strength of our diverse species and geographic presence. Performance was particularly strong in Asia, led by China, whilst ABS was impacted by challenging trading conditions, particularly in Europe. "The announcement of the first pigs resistant to the devastating PRRS virus, developed through gene editing with the University of Missouri, was a very significant milestone in the history of our industry. We are seeing the early fruits of our strong commitment to lead in innovation through R&D. We are excited by the prospects this has for animals, our customers and our business and will continue to commit increasing resources to our R&D programmes. "Our confidence in the strategy for the business and in the future prospects for the Company is reflected in the 10% increase in our interim dividend. We expect to make further good progress during the second half of the year and we anticipate that our full year performance will be in line with our objectives."
- 11 Aug 2016 08:29
- 17 of 30
Genus, a global pioneer in animal genetics, has announced the first jury verdicts in its anti-trust litigation against Inguran LLC, operating as Sexing Technologies ('ST'), relating to ABS's Genus Sexed Semen processing technology.
At the trial, in the US District Court for the Western District of Wisconsin where the verdicts were announced yesterday, the jury found that ABS and Genus had proved that ST had wilfully maintained monopoly power in the market for sexed bovine semen processing in the US since July 2012.
The jury also found that Genus had not proved that it had suffered injury as a result of ST's wilful maintenance of monopoly power.
The jury has still to consider ST's counter claims related to two of its US patents (numbers 8,206,987 and 8,198,092) and ST's counter claims that Genus breached confidentiality obligations under the 2012 semen sorting agreement between the parties.
The jury is expected to deliver verdicts on these matters shortly. In addition the jury will also consider, if applicable, a verdict on damages in relation to these matters later this week.
GSS is a novel technology for sexing bovine semen that does not subject the sperm cells to high pressures and forces. Dairy farmers have a preference for female calves, and the use of gender skewed sexed semen in artificial insemination provides customers with female calves from ABS's elite genetic lines.
The commercial launch of GSS product would provide ABS customers and third party bull studs with an alternative service provider and increased competition in the market for the processing of sexed bovine semen.
Genus will update the market as further verdicts are announced and as post verdict motions are considered.
- 08 Sep 2016 08:03
- 18 of 30
Genus, a leading global animal genetics company, reports significant strategic progress and continued profit growth in the year to the end of June.
Adjusted profit before tax rose 7% to £49.7m (up 10% in constant currency), driven by strong performances in Genus PIC and Genus Asia, particularly China.
Statutory profit before tax rose 5% to £60.9m including a pension related exceptional credit of £44.2m (2015: £0.4m) and a reduction in the value of biological assets £17.1m (2015: £24.9m increase).
Adjusted basic earnings per share rose 7% to 60.7p (up 10% in constant currency) and statutory basic earnings per share increased 23% to 81.1p reflecting a lower statutory tax rate on adjusting items.
Revenue of £388.3m, reduced 3% due to lower bovine volumes in tough dairy markets and lower porcine by-product and up-front sales. Growth of 17% (14% in constant currency) in strategically important royalty revenues.
Chief executive Karim Bitar said: "Genus performed well overall in 2016 with another year of double digit constant currency profit growth and substantial strategic progress in our R&D endeavours in addition to growth in key markets such as China.
"We established gene editing as a core strategic longer term growth platform in Genus that offers considerable opportunity in disease resistance which will benefit animals, customers and consumers. Our GSS technology is ready for commercial launch and we expect to have legal clarity in the coming months on when we will be able to bring it to market.
"To pursue our long-term growth objectives, we plan to increase R&D investment in FY17 and therefore expect broadly stable constant currency results, however exchange rates should provide a benefit to the reported numbers.
"Overall we expect to perform in line with market expectations. We are confident in the future of the business and are proposing a 10% increase in the dividend."
- 23 Feb 2017 09:46
- 19 of 30
Genus, a leading animal genetics company, reports adjusted pre-tax profits of £25.1m for the six months to the end of December - 5% up at actual currency but 10% down on a constant currency basis.
Revenues of £222.1m were up 18% on an actual basis and 3% higher at constant currencies.
On a statutory basis, operating profits were flat at £10.0m and pre-tax profits were 12% lower at £11.4m.
The interim dividend of 7.4p per share, which is payable on 31 March, is 10% up on last time.
Genus also announced that it has signed an agreement to enter into a strategic partnership covering the supply of porcine genetics in several markets.
PIC, Genus's porcine division, will acquire the genetic rights and intellectual property of Hermitage.
Hermitage will also become a strategic supply chain and distribution partner for PIC.
In addition, PIC will acquire certain Hermitage customer relationships in various geographies including Russia, the US and several European countries.
The transaction is subject to a number of closing conditions which are expected to be fulfilled by the end of March
- 23 Mar 2017 11:03
- 20 of 30
Berenberg today initiates coverage of Genus PLC (LON:GNS) with a hold investment rating and price target of 1800p.
- 09 Jun 2017 10:12
- 21 of 30
Genus is facing new patent infringement litigation in the US.
The company - a global pioneer in animal genetics - said Inguran, XY and Cytonome/ST, (collectively ST) had filed patent infringement proceedings against ABS Global, Genus and Premium Genetics (UK) (collectively ABS) in the US District Court for the Western District of Wisconsin.
Genus said: "The new litigation alleges that ABS infringes seven ST patents and asserts trade secret and breach of contract claims."
It said that ABS intended to vigorously defend ST's latest legal action.
An update said: "The litigation is part of the long running dispute between ST and ABS in connection with the development and launch of Genus Sexed Semen technology (GSS), a proprietary product designed to compete with ST's monopoly in the processing of sexed bovine semen.
"In previous litigation initiated by ABS, the court for the Western District of Wisconsin awarded ABS a permanent injunction against ST based on the finding that ST had wilfully maintained an illegal monopoly in the market for sexed bovine semen processing in the US since July 2012.
"The court also found ABS had infringed two ST patents and awarded damages and post judgment royalties.
"ABS has filed a notice of appeal on one of these patents and an inter-partes review oral hearing at the US Patent Office is scheduled shortly on the other.
"The US Patent Office had earlier found two other ST patents challenged by ABS to be unpatentable."